We had an in-depth conversation with Dr Fick, unpacking recent developments in HIV prevention research in South Africa. The discussion focused on Lenacapavir and its potential to transform HIV prevention efforts, particularly among young people and other high-risk groups. Dr Fick broke down how the treatment works, its significance within ongoing clinical research, and the potential impact it could have on reducing new HIV infections and advancing public health outcomes in South Africa.